Vanya Beltrami

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

Part of Taconic Biosciences, Inc., M&B AS breeds laboratory mice and rats for the scientific community. The company is based in Ry, Denmark. M&B was acquired by Taconic Biosciences, Inc. on May 01, 2002.

StemCare A/S operates as a private stem cell bank. The firm stores stem cells from umbilical cord blood. The company was founded by Sten Verland in 2003 and is headquartered in Gentofte, Denmark.

Synexus Compass, Inc. provided medical image-analysis, subject-recruitment and biochemical marker services that enable life-science industry clients to execute clinical trials while decreasing the time, uncertainty and cost of product development. The company was founded in 1998 and was headquartered in San Francisco, CA.

Genobiotix ApS engages in research and experimental development on biotechnology. It develops and commercializes methods for producing new antibiotics. The company was founded by Kenn Axø Gerdes and Anders Løbner-Olesen on January 23, 2004 and is headquartered in Bagsvaerd, Denmark.

Scanbur A/S engages in the production and supply of housing, cage changing, cleaning, and decontamination equipment for animal research facilities. It also offers bedding and nesting materials, as well as air handling units. The company was founded on December 18, 1975 and is headquartered in Karlslunde, Denmark.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Verland Capital ApS (Verland Capital) is an independent venture capital firm headquartered in Bagsværd, Denmark. The firm was founded in 1994 by Sten Verland.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

The Danish Venture Capital & Private Equity Association is an organization that represents business owners who are members of the association. The private company is based in Copenhagen, Denmark. The Danish company has recently released their annual activity report for the entire ecosystem of active ownership. The report can be downloaded from their website. Additionally, they have listed six specific wishes for political party leaders on their website. and has subsidiaries in Denmark.

Zymenex Holding A/S engages in the research and development of therapeutics for life threatening diseases. The company is headquartered in Hillerod, Denmark.

Tera Holding A/S provides commercial property rental services. The private company is based in Karlslunde, Denmark.

STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark.

Skovlyst Production A/S operates a brewery restaurant. It serves a hand-brewed beer from elderflower, birch sap, beech twigs, woodruff, and nettles. The firm also offers a combined picnic with beer tasting. The company was founded by Casper Mikkel Møller on February 21, 2007 and is headquartered in Birkerød, Denmark.

Fondation Soins Intensifs & Centre Brûlés Centre Hospitalier is a medical services provider based in Lausanne, Switzerland. The Swiss company provides medical services and is ultimately controlled by the Government of Switzerland.

Centre Hospitalier Universitaire Vaudois is a university hospital located in Lausanne, CH. The SwitzerlandUV is also a renowned center of medical education and research, collaborating with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). It has 16 clinical and medico-technical departments and is known for its academic achievements in healthcare, research, and teaching. The vast campus in the lake region is home to these institutions. The CEO of the Swiss company is Nicolas Demartines.

LS Pharma International SA provides administrative and accounting assistance services. The private company is based in Geneva, Switzerland.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon.

Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors.

Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark.

Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.

Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Unitectra Ltd. operates as a technology transfer organization. It specializes in licensing, research contracts, IP management, start-up consulting and pre-seed financing. The company was founded by Adrian Sigrist in 1999 and is headquartered in Zurich, Switzerland.

Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.